Third Quarter 2026
Filed Nov 6, 2026Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities
The August 2026 IPO materially increased liquidity and the Company initiated the EMERGE Phase 2b PBH study, while third-quarter net loss increased to $4.9 million, principally reflecting $3.4 million in change in warrant liability alongside higher R&D and G&A spending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $1,079,000 | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $703,736 | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $1,782,736 | – | – |
| Change in fair value of warrant liability, three months ended September 30, 2026GAAP | $(3,436,669) | – | – |
| Change in fair value of convertible promissory notes payable, related party, three months ended September 30, 2026GAAP | $(26,777) | – | – |
| Interest income, three months ended September 30, 2026GAAP | $338,579 | – | – |
| Total other (expense) income, three months ended September 30, 2026GAAP | $(3,124,867) | – | – |
| Net loss, three months ended September 30, 2026GAAP | $(4,907,603) | – | – |
| Net loss per common share, basic and diluted, three months ended September 30, 2026GAAP | $(0.47) | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 10,404,831 | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $1,473,697 | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $1,127,576 | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $2,601,273 | – | – |
| Change in fair value of warrant liability, nine months ended September 30, 2026GAAP | $(3,426,761) | – | – |
| Change in fair value of convertible promissory notes payable, related party, nine months ended September 30, 2026GAAP | $(78,177) | – | – |
| Interest income, nine months ended September 30, 2026GAAP | $338,726 | – | – |
| Total other (expense) income, nine months ended September 30, 2026GAAP | $(3,166,212) | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $(5,767,485) | – | – |
| Net loss per common share, basic and diluted, nine months ended September 30, 2026GAAP | $(0.82) | – | – |
| Weighted average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 6,995,883 | – | – |
What drove it
- R&D expense increased primarily due to $714 thousand in direct program expenses for the PBH EMERGE Phase 2b study and expanded department headcount.
- G&A expense reflected $237 thousand in personnel costs and $214 thousand in incremental public company operational expenses.
- The Company completed its $93.4 million IPO in August 2026, issuing and selling 7,187,500 shares of common stock at $13.00 per share, including 937,500 additional shares pursuant to the underwriter's option.
- The Company received net proceeds from the IPO of approximately $84.4 million after deducting underwriting discounts, commissions and offering expenses.
- The third-quarter net loss reflected operating expenses of $1.8 million, change in warrant liability of $3.4 million, offset by interest income of $0.3 million.
Concerns
- Vogenx reported a net loss of $4.9 million for the three months ended September 30, 2026, versus a net loss of $284 thousand for the same period in 2025.
- The change in fair value of warrant liability was $(3,436,669) for the three months ended September 30, 2026.
- The filing identifies a need for additional capital and material weaknesses in internal control over financial reporting among its risks.
- The Company has a limited operating history and its clinical plans are subject to risks related to trial initiation, timing, enrollment and results.
What to watch
- Topline results from the EMERGE Phase 2b study are expected in the second half of 2027.
- EMERGE is evaluating mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 adults with PBH.
- The Company plans to initiate a Phase 2 study of mizagliflozin for gastroparesis in the first half of 2027.
- Deployment of the approximately $84.4 million in IPO net proceeds and the resulting cash, cash equivalents, and marketable securities position of $82.1 million.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $5,126,137; as of December 31, 2025: $601,010.
- Marketable securities as of September 30, 2026: $76,991,943; as of December 31, 2025: -.
- Cash, cash equivalents, and marketable securities as of September 30, 2026: $82.1 million; as of December 31, 2025: $601 thousand.
- Prepaid expenses and other current assets as of September 30, 2026: $725,193; as of December 31, 2025: $16,797.
- Total current assets as of September 30, 2026: $82,843,273; as of December 31, 2025: $681,170.
- Accounts payable as of September 30, 2026: $523,570; as of December 31, 2025: $62,964.
- Accrued expenses as of September 30, 2026: $318,900; as of December 31, 2025: $709,818.
- Warrant liability as of September 30, 2026: -; as of December 31, 2025: $11,323.
- Convertible promissory notes payable, related party, as of September 30, 2026: -; as of December 31, 2025: $816,300.
- Total current liabilities as of September 30, 2026: $842,470; as of December 31, 2025: $1,600,405.
- Total stockholders' equity (deficit) as of September 30, 2026: $82,000,803; as of December 31, 2025: $(919,235).
- Cash flow from operations, capital expenditures, and free cash flow were not reported.
Analysis
Vogenx is a clinical-stage company and did not report revenue or commercial segments. The period centered on development execution following the August 2026 IPO. In October 2026, the Company initiated EMERGE, a randomized, placebo-controlled, double-blind, parallel-group Phase 2b study of mizagliflozin 5 mg and 10 mg for 28 days in approximately 36 adults with PBH.
Third-quarter operating expenses were $1,782,736, compared with $302,477 for the same period in 2025. R&D expense was $1,079,000, compared with $124,813, driven primarily by $714 thousand in direct program expenses for the PBH EMERGE Phase 2b study and expanded department headcount. G&A expense was $703,736, compared with $177,664, reflecting $237 thousand in personnel costs and $214 thousand in incremental public company operational expenses.
Net loss was $(4,907,603), or $(0.47) per basic and diluted share, compared with $(284,407), or $(0.05) per basic and diluted share. Beyond operating costs, the result included a $(3,436,669) change in fair value of warrant liability, partly offset by $338,579 of interest income. For the nine months ended September 30, 2026, net loss was $(5,767,485), while total operating expenses were $2,601,273.
Liquidity changed materially after the IPO. The Company reported $82.1 million in cash, cash equivalents, and marketable securities as of September 30, 2026, compared with $601 thousand as of December 31, 2025. The IPO generated approximately $84.4 million of net proceeds after underwriting discounts, commissions and offering expenses. The Company did not provide financial guidance, but stated that EMERGE topline results are expected in the second half of 2027 and that it plans to initiate a gastroparesis Phase 2 study in the first half of 2027.
Management, verbatim
Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August,
James Green, Chief Executive Officer of Vogenx
The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.
James Green, Chief Executive Officer of Vogenx
Not in the filing
stated, not guessed- Total revenue
- Revenue by segment
- Gross profit and gross margin
- Operating income or loss
- Non-GAAP measures
- Operating cash flow
- Capital expenditures
- Free cash flow
- Financial guidance
- Tax rate
- Dividend or share repurchase activity
- Prior-quarter comparisons
- Cash runway
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.